跳至主要内容
临床试验/NCT03126994
NCT03126994已完成不适用

Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer

PhysioWave, Inc.2 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2017年4月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
160
试验地点
2
主要终点
Primary Objective: PWV Equivalence

研究概览

简要总结

This is a prospective, single-center, non-randomized validation study being conducted under a non-significant risk study design with the primary aim to evaluate PWV, PR, and BW accuracy in a sample of subjects representative of the US general adult population. The primary study objective is to demonstrate equivalency when measuring: Pulse Wave Velocity (PWV) and Pulse Rate (PR) between the PhysioWave Cardiovascular Analyzer (CA) and AtCor Medical SphygmoCor® XCEL PWA & PWV (XCEL), and Body Weight (BW) between the CA and the Detecto Solo Digital Healthcare Scale (Detecto).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects >18 years old
  • Subject signs a written Informed Consent form to participate in the study, prior to any study procedures
  • Subgroup Inclusion Criteria
  • Subject has been taking ACE Inhibitors or Angiotensin Receptor Blockers for at least 30 days

排除标准

  • Known significant carotid or femoral artery stenosis
  • Non-palpable (non-detectable) arterial pulse at the sites of measurements
  • Pacemaker, defibrillator, or other cardiac stimulator
  • Erratic, accelerated or mechanically controlled irregular heart rhythm, or an arrhythmia
  • History of cardiac valve disorder or cardiac valve disease
  • History of venous disease, including venous insufficiency or deep vein thrombosis
  • History of peripheral artery disease
  • Requirement for supplemental oxygen
  • Neuromuscular disorders that cause shaking or tremors (such as Parkinson's disease or Multiple Sclerosis), or other disease or condition affecting balance
  • Amputation or malformation of any limb or extremity (foot, leg, or arm) which would impede the placement of blood pressure cuffs or standing on the scale with two feet.
  • Known or suspected pregnancy
  • Inability to provide informed consent
  • Mental incompetence or a prisoner status
  • Current participation in a clinical trial of another investigational drug or device in which the study endpoint has not been met
  • BMI > 40
  • Subjects > 400 lbs
  • Subjects on strong vasoactive drugs, such as those used to control high blood pressure, for <30 days
  • Blood loss or blood donation of ˃ 550 mL within 30 days before study procedure

研究组 & 干预措施

PhysioWave Cardiovascular Analyzer

Experimental

The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.

干预措施: PhysioWave Cardiovascular Analyzer (Device)

PhysioWave Cardiovascular Analyzer

Experimental

The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.

干预措施: AtCor XCEL PWA & PWV (Device)

PhysioWave Cardiovascular Analyzer

Experimental

The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.

干预措施: Detecto SOLO (Device)

结局指标

主要结局

Primary Objective: PWV Equivalence

时间窗: Day 1

The first primary study objective is to demonstrate equivalency when measuring: pulse wave velocity (PWV) (in m/s) between the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA \& PWV.

Pulse Rate Equivalence

时间窗: Day 1

The second primary study objective is to demonstrate equivalency when measuring: pulse rate (in bpm) between the PhysioWave Cardiovascular Analyzer and AtCor Medical SphygmoCor® XCEL PWA \& PWV.

Body Weight Equivalence

时间窗: Day 1

The third primary study objective is to demonstrate equivalency when measuring body weight (in kg) between the PhysioWave Cardiovascular Analyzer and the Detecto Solo.

次要结局

  • Secondary Objective: Precision Analysis, Pulse Rate(Day 1 or Day 2)
  • Secondary Objective: BMI Equivalence(Day 1)
  • Secondary Objective: Precision Analysis, PWV(Day 1 or Day 2)
  • Secondary Objective: Precision Analysis, Body Weight(Day 1 or Day 2)
  • Secondary Objective: Precision Analysis, BMI(Day 1 or Day 2)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验